Randomized Phase 3 Evaluation of Lower Dose (3-2-1 Strategy) vs. Full Dose of Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia

较低剂量（3-2-1 策略）与全剂量依鲁替尼治疗慢性淋巴细胞白血病的随机 3 期评估

• 批准号: 437565
• 负责人: Hay Annette
• 金额: $ 7.29万
• 依托单位: Queen's University (Kingston, Ontario)
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2020
• 资助国家: 加拿大
• 起止时间: 2020-10-01 至 2021-10-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=437565&lang=en
• 关键词: Chronic Lymphocytic Leukemia; De-Escalation; Non-Inferiority; Randomized Controlled Trial; Toxicity; Chronic Lymphocytic Leukemia; De-Escalation; Non-Inferiority; Randomized Controlled Trial; Toxicity

Chronic lymphocytic leukemia (CLL) is an incurable blood malignancy with a long natural history, typically characterized by multiple recurrences and repeated requirement for treatment. Ibrutinib (Imbruvica®) has emerged as an effective novel therapy for t

慢性淋巴细胞性白血病（CLL）是一种无法治愈的血液恶性肿瘤，自然史，通常以多种回报和对治疗的重复要求进行特征。 Ibrutinib（Imbruvica®）已成为一种有效的T